Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.


Related Content

Deal Watch: AbbVie, arGEN-X To Explore Immuno-Oncology According To GARP
Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
J.P. Morgan Notebook, Jan. 13: Regeneron, AstraZeneca, CRISPR And Juno
AstraZeneca's Gout Dilemma: Should Smaller, More Frequent Lesinurad Dose Be Studied?
AstraZeneca’s Gout Treatment OK, But Post-Marketing Studies Needed
AstraZeneca’s Gout Drug Lesinurad May Face Risk Management Issues
Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape
Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts